BioNxt Solutions Inc.
15.8.2024 22:04:41 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
Family Online Safety Institute Hosts 2026 European Forum in Brussels, Convening Global Leaders to Find Common Ground on Online Safety9.6.2026 07:30:00 CEST | Press release
New Research on Australia's Social Media Ban Released Alongside Day of Sessions with OECD, Ofcom, and Global Industry Leaders BRUSSELS, BE / ACCESS Newswire / June 9, 2026 / The Family Online Safety Institute (FOSI) is pleased to host its 2026 European Forum, "Finding Common Ground," taking place today at Google's offices in Brussels, Belgium. This Forum brings together policymakers, regulators, researchers, industry leaders, and civil society organizations from across Europe and beyond to explore one central question: how can we find common ground on online safety? Throughout the day, attendees will explore developments in online safety regulation, emerging research on children's digital wellbeing, the growing role of AI in the lives of families, and realistic approaches to creating safer digital experiences for young people and families. Featured sessions include a discussion with representatives from the OECD, Ofcom, and Arcom, ATKM, and Belgium's Institute for Postal Services and T
Three Polaris Projects in Mexico Selected Under the Mixed Development Program9.6.2026 01:40:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 8, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announced that Mexico's Secretary of Energy (Secretaría de Energía, "SENER"), and the Federal Electricity Commission (Comisión Federal de Electricidad, "CFE") have completed the first national competitive selection process under the CFE Mixed Development Program. The process was launched through a Request for Proposals ("RfP") issued in February 2026, with submitted projects evaluated in accordance with the Guidelines for Mixed Development Programs published by SENER in January 2026. On June 5, 2026, CFE and SENER announced that the final award volume exceeded the original target, with approximately 8,000 MW of projects selected for advancement under the program. As part of this award process, Polaris is pleased to announce that all three Polaris-owned projects submitted under the Mixed Development Program have been selected to advance to the final contract negotiation st
GA-ASI Announces Investments in Six Dutch Companies8.6.2026 18:00:00 CEST | Press release
New Slate of Business Partnerships Established Following the Last Blue Magic Netherlands Event SAN DIEGO, CA / ACCESS Newswire / June 8, 2026 / General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative. These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities. Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom